Rationale: Peroxisome proliferator-activated receptor (PPAR)␥ agonists attenuate atherosclerosis and abdominal aortic aneurysms (AAAs). PPAR␥, a nuclear receptor, is expressed on many cell types including smooth muscle cells (SMCs).
T hiazolidinediones (TZDs), including rosiglitazone and pioglitazone (Pio), are used widely to improve insulin sensitivity in patients with type 2 diabetes. Experimentally, TZDs reduce atherosclerosis in both low-density lipoprotein receptor (LDLR) Ϫ/Ϫ and apolipoprotein (Apo)E Ϫ/Ϫ mice. 1, 2 Recent studies have demonstrated that TZDs also reduce Ang II-induced abdominal aortic aneurysm (AAA) development in ApoE Ϫ/Ϫ mice. 3, 4 The molecular target for TZD is PPAR␥, a nuclear receptor that is highly expressed in all cell types involved in vascular pathologies, including macrophages, endothelial cells, and smooth muscle cells (SMCs). 5 Currently, it has not been defined whether the beneficial effects of TZDs are attributable to PPAR␥ agonism in a specific cell type. Furthermore, it has been suggested that TZDs may exert some of their biological effects through PPAR␥-independent mechanisms, although this has not been defined in vascular pathologies. 6 TZDs have been demonstrated to regulate important SMC functions, including proliferation and migration. 7 SMCspecific genetic manipulations have resulted in changes in both atherosclerosis 8, 9 and AAAs in mice. 9 Furthermore, SMC-specific gene deletion of PPAR␥ results in changes in blood pressure and injury-induced vascular hyperplasia. 10, 11 However, no studies have currently determined whether the benefits of TZDs on vascular pathologies are mediated via a SMC-specific PPAR␥-dependent mechanism.
To elucidate a role of SMC-specific PPAR␥ expression on TZD-induced reductions in atherosclerosis and AAAs, we bred female LDLR Ϫ/Ϫ mice harboring PPAR␥ floxed genes to similarly genetically manipulated males that were hemizygous for Cre regulated by the SM22 promoter. This breeding strategy generated littermate controls that were either wild-type or SMC-specific deficient in PPAR␥. Using these mice, we determined the contribution of PPAR␥ expression in SMCs to the effects of Pio on Ang II-induced atherosclerosis and AAAs. 12 The results demonstrate that SMC-PPAR␥ deficiency resulted in increased Ang II-induced atherosclerosis. Furthermore, these data demonstrate that PPAR␥ expression in SMCs is a major contributor to Pio-induced reduction in atherosclerosis. Contrary to previous studies, we did not discern an effect of Pio on Ang II-induced AAAs.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results

Generation of LDLR ؊/؊ Mice With SMC-Specific PPAR␥ Deficiency
To verify the genotype of mice, aortas were dissected free, adventitia and endothelium were removed, and DNA was isolated from SMC-containing media. PCR analyses were performed on DNA isolated from the arch, thorax, suprarenal, and infrarenal aortic regions to determine the uniformity of Cre-based exon excision. These analyses demonstrated the presence of nonfunctional alleles (240-bp amplicon) throughout aortas of Cre-expressing mice. In contrast, aortas from nontransgenic littermates generated 215-bp amplicons derived from intact floxed genes ( Figure 1A ).
RT-PCR analyses showed complete deletion of PPAR␥ mRNA in SMC aortic medias of Cre ϩ/0 mice ( Figure 1B) , indicating that functional PPAR␥ transcripts were ablated. Western blot analyses demonstrated that PPAR␥ protein was ablated in aortic SMCs from Cre ϩ/0 mice, while not influencing abundance in liver, kidney, and adipose tissue ( Figure 1C and Online Figure II ).
SMC-Specific Deficiency of PPAR␥ Augmented Ang II-Induced Atherosclerosis Without Affecting AAAs
SMC-specific PPAR␥ deficiency in LDL receptor Ϫ/Ϫ mice resulted in significant (PϽ0.05) increases in Ang IIinduced atherosclerotic lesion areas in male mice, but had no effect in females ( Figure 2 , A and B). SMC-specific deletion of PPAR␥ had no effect on body weight, plasma total cholesterol concentrations (Online Table I ), or lipoprotein-cholesterol distributions (data not shown). Ang II infusion significantly increased systolic blood pressure (SBP) in male mice of both groups (Online Table I ). SMC-specific PPAR␥ deficiency had no effect on Ang IIinduced AAA formation ( Figure 2C ) or aortic rupture (Cre 0/0 , 25%; versus Cre ϩ/0 , 28%) in either sex.
Pio Attenuated Ang II-Induced Atherosclerosis Only in the Presence of PPAR␥ in SMCs
In Ang II-infused mice fed a fat-enriched diet, PPAR␥ mRNA abundance was not significantly increased in peritoneal macrophages (Online Figure III) . Pio administration to these mice induced PPAR␥ mRNA abundance and activity in selected cell types and tissues, including macrophages, liver, kidney, and adipose. These inductions did not differ between Cre 0/0 and Cre ϩ/0 mice ( Figure 3A PPAR␥ deficiency ( Figure 3C and 3D) . In contrast, Pio administration significantly attenuated Ang II-increased SBP equivalently in both Cre 0/0 and Cre ϩ/0 groups (Online Table II ). Pio administration had no effect on body weight, plasma total cholesterol concentrations (Online Table II ), or lipoprotein cholesterol distributions (data not shown). AAA formation ( Figure 3E ) or aortic rupture (Cre 0/0 , 11%; versus Cre ϩ/0 , 20%) was not different between groups.
Immunostaining of atherosclerotic lesions with ␣-actin demonstrated uniform reactivity throughout the medial intralaminar spaces of all groups, but minimal SMC immunostaining was detected in atherosclerotic lesions from any group. Although PPAR␥ deficiency increased lesion size, immunostaining for macrophages was dominant in atherosclerosis from both Cre 0/0 or Cre ϩ/0 mice.
Ang II Augmented Monocyte Chemoattractant Protein-1 Production in PPAR␥-Deficient SMCs
To define potential mechanisms of Pio reducing atherosclerosis, plasma monocyte chemoattractant protein (MCP)-1 concentrations were measured. No significant difference was observed among groups demonstrating no systemic effect on MCP-1 (Online Figure VII) .
Aortic SMCs cultured from either Cre 0/0 or Cre ϩ/0 mice were incubated with Pio (20 mol/L) for 24 hours, and with or without Ang II (1 mol/L) for a further 18 hours. Ang II significantly increased MCP-1 concentrations from Cre ϩ/0 SMCs but had no significant effect on Cre 0/0 SMCs ( Figure  4 ). Coincubation with Pio had no effect on Ang II-induced MCP-1 production in Cre ϩ/0 SMCs.
Consistent with SMCs harvested from Cre 0/0 and Cre ϩ/0 mice, Ang II increased MCP-1 concentrations in media of SMCs cultured from mice expressing a dominant-negative mutation of PPAR␥ P465L (PPAR␥ Lϩ ) 13 but not in cells isolated from nontransgenic littermates. To determine whether PPAR␥ has a dominant effect on MCP-1 secretion, SMCs were incubated with interferon (IFN)␥. In contrast to Ang II, IFN␥ (300 U/mL) significantly increased MCP-1 concentrations in media of SMCs from both strains ( Figure 4B ). Pio had no effect on IFN␥induced MCP-1 ( Figure 4C ).
To confirm that the effects of Pio on MCP-1 were attributable to interactions with PPAR␥, Cre 0/0 and Cre ϩ/0 SMCs were incubated with Pio and Ang II as described above. The absence of PPAR␥ in SMCs significantly lowered AP2 mRNA abundance but failed to affect CD36 (Online Figure VIII) . Ang II incubation significantly reduced mRNA abundance of both these target genes in Cre ϩ/0 SMCs. Coincubation of Ang II and Pio significantly attenuated the reduced mRNA abundance of target genes in SMCs from Cre 0/0 but not Cre ϩ/0 mice.
Discussion
In the present study, we demonstrate that SMC-specific PPAR␥ deficiency augments Ang II-induced atherosclerosis in male LDLR Ϫ/Ϫ mice. Interestingly, Pio administration attenuates Ang II-induced atherosclerosis only in wild-type mice, but not in SMC-specific PPAR␥-deficient mice, which characterizes SMC-specific PPAR␥ as the key molecular target for the ligand-mediated attenuation of atherosclerosis.
SMC-specific PPAR␥ deficiency augmented Ang II-induced atherosclerosis only in male mice. This is in agreement with the study by Li et al, in which the attenuation of atherosclerosis by a PPAR␥ ligand was observed only in male LDLR Ϫ/Ϫ mice. 1 The basis for these sex differences have not been defined.
Pio administration activates PPAR␥ in both Cre 0/0 and Cre ϩ/0 genotypes, which was evidenced by increased PPAR␥ expression observed in peritoneal macrophages and other tissues. Previous in vitro studies demonstrated that TZDs inhibited SMC proliferation and induced apoptosis through PPAR␥-dependent mechanisms. 14 In the present study, Pio administration attenuates Ang II-in-duced atherosclerosis only in Cre 0/0 mice, but not in mice with SMC-specific PPAR␥ deficiency. Considering that SMC proliferation constitutes an important cellular mechanism for atherosclerosis initiation, 15 our findings not only demonstrated SMC-specific PPAR␥ as an endogenous inhibitor of atherosclerosis but also established that TZDs exert antiatherosclerotic effects through this pathway.
Pio administration significantly suppresses Ang II-induced SBP in both genotypes. This result indicates that Piomediated SBP-lowering effect is independent of SMCspecific PPAR␥. In support of this observation, a recently published study using both SM22-Cre ϩ and Tie2-Cre ϩ PPAR␥ flox mice showed that TZD-mediated the SBPlowering effects via PPAR␥ expressed in endothelium. 16 Because endothelial PPAR␥ is intact, Pio administration attenuates Ang II-induced SBP in both Cre 0/0 and Cre ϩ/0 groups in our study.
SMC-specific PPAR␥ deficiency or Pio administration did not influence aneurysm formation in LDLR Ϫ/Ϫ mice, which is contrary to a recent publication in which Pio reduced suprarenal aortic expansion in Ang II-infused ApoE Ϫ/Ϫ mice. 4 The differences may be attributable to the lower dose used in the present study. 4 Our dietary delivery was estimated to be Ϸ20 mg/kg per day, whereas the drinking water delivery in the study by Golledge et al 4 was estimated to be 50 mg/kg per day. In another study, rosiglitazone attenuated Ang II-induced AAA formation in ApoE Ϫ/Ϫ mice, which was mainly associated with decreased expression of inflammatory mediators. 3 The basis for the inconsistent effects of TZDs on Ang II-induced AAAs is unclear.
To further understand the mechanism by which Pio mediates its effect via SMC-PPAR␥ on atherosclerosis, we examined the effect of Ang II on MCP-1 production in cultured Cre ϩ and PPAR␥ Lϩ SMCs. Interestingly, Ang II activates MCP-1 production only in Cre ϩ/0 and PPAR␥ Lϩ SMCs, but not in control SMCs, suggesting that endogenous SMC-PPAR␥ regulates Ang II-induced MCP-1 production. In addition, Pio had no effect on Ang II-induced MCP-1 production in Cre ϩ/0 SMCs, which is consistent with this TZD requiring interaction with PPAR␥ to reduce Ang II-induced atherosclerosis. The specificity of this pathway was demonstrated by the continued induction of MCP-1 secretion in PPAR␥ Lϩ cells during IFN␥ incubation that signals via CD74 pathway in SMCs. 17 This SMC-PPAR␥-dependent effect of Ang II is localized to SMCs, which is not reflected by plasma concentrations of MCP-1.
In summary, this study provides evidence that lack of PPAR␥ in vascular SMCs results in significant increases in atherosclerosis associated with increased MCP-1 production. Furthermore, the study reveals that SMC-specific PPAR␥ expression is a novel mediator of ligand-mediated attenuation of atherosclerosis.
